16 results about "Response element" patented technology

The present disclosure provides DNA molecules, such as transfer plasmids, useful for manufacturing packaged retroviral vectors encoding a therapeutic protein such as chimeric antigen receptors (CARs) and T cell receptors (TCRs). The encoded retroviral transcript in the DNA molecule includes a transgene, an elongation factor 1-alpha 1 (EFla) promoter, without the EFla intron, operably linked to the transgene and a Rev response element (RRE).

The invention relates to the technical field of gene engineering detection, and particularly discloses a gene detection system for promoting andrographolide synthesis based on a biosensor, a key gene ApDof29 for regulating and controlling andrographolide synthesis is determined through whole genome analysis, gene expression profile research and co-expression network analysis, the core regulation and control effect of ApDof29 is verified, and the gene detection system for promoting andrographolide synthesis based on the biosensor is used for promoting andrographolide synthesis. The invention also develops a real-time dynamic monitoring system, and realizes non-invasive monitoring of andrographolide content accumulation, biosynthesis rate and metabolic intermediate concentration change by utilizing the fusion of a specific response element and a reporter gene. Through comprehensive calculation processing of an accumulation abnormal coefficient, a synthesis rate abnormal coefficient and a concentration change abnormal coefficient, the regulation and control effect of ApDof29 is dynamically evaluated, and a scientific basis is provided for subsequent gene modification.

The invention belongs to the technical field of medical chemistry, and discloses an aza aromatic amine protein degradation targeting chimera (PROTAC) compound with the activity of degrading nuclear receptor co-inhibitor 1 (NCoR1) in a targeting manner, and a preparation method and application of the aza aromatic amine protein degradation targeting chimera (PROTAC) compound. The aza aromatic amine compound is prepared through acylation and N-alkylation reaction, and the structure of the compound is shown as a formula I to a formula IV. A Liver X Receptor Response Element-Luciferase reporter gene system (LXRE-Luc luciferase reporter gene system) determination experiment shows that when the compound is 10 [mu] M, the compound has an obvious liver receptor (LXR) regulation effect, and the compound has an obvious liver receptor regulation effect when the compound is 10 [mu] M; western blot experiment research shows that the compound has a remarkable degradation effect on NCoR1, and the compound XH-10 with the highest activity can generate a remarkable NCoR1 degradation effect when the concentration is 5 mu M. The compound is PROTAC with NCoR1 targeted degradation activity, and has the advantages of high activity and simple preparation process. The compound has an important value in the aspect of glycometabolism and ester metabolism regulation medicine development.

Provided herein are nucleic acid constructs comprising one or more Nuclear Factor of Activated T-cells (NFAT) response elements and an expressible nucleic acid sequence encoding a first engineered polypeptide monomer, wherein the first engineered polypeptide monomer comprises a regulatable polypeptide payload and at least one drug response domain (DRD). The abundance, availability, and / or biological activity of the payload is regulated by interaction of an effective amount of an immune cell stimulator with the one or more NFAT response elements and by interaction of an effective amount of a ligand with the one or more DRDs.

The present disclosure provides high-performance immune-activation reporter cell line set. A set of nucleic acid constructs comprising one or more response elements operatively linked to a TATA box motif promoter or a minimal IL-2 promoter are provided. A set of reporter cell lines comprising a polynucleotide sequence encoding a reporter protein under the control of one or more response elements operatively linked to a TATA box motif promoter or a minimal IL-2 promoter is also provided. The provided set of reporter cells enable sensitive and signal-enhanced bioassay performance to reflect and evaluate adaptive immune cell activation / inhibition regulated by the immune receptors CD3, co-stimulatory CD28 and related signaling pathways, and avoid responding bias triggered by particular transcription factor. A controllable engineer method for a functional cell line is further provided.

Nucleic acid constructs comprising one or more activated T-cell nuclear factor (ATNF) response elements and an expressible nucleic acid sequence encoding a first manipulated polypeptide monomer are provided herein, wherein the first manipulated polypeptide monomer comprises a tunable polypeptide payload and at least one drug-sensitive domain (DSD). The abundance, availability, and / or biological activity of the payload are regulated by the interaction of an effective amount of immune cell-stimulating agent with the one or more ATNF response elements and by the interaction of an effective amount of ligand with the one or more DSDs.

This invention relates to the field of gene editing technology, specifically to a gene circuit-based specific gene expression system and module, a pharmaceutical composition, and its applications. The system includes a first vector and a second vector. The first vector includes a first expression cassette containing a cell-specific promoter, a coding sequence encoding a transcriptionally activated fusion protein, and a regulatory region sequence downstream of the coding sequence. The regulatory region sequence is configured to form a response element in the 3' untranslated region of the fusion protein's mRNA after transcription. This response element binds to a specific long non-coding RNA within the silenced cell, leading to the degradation of the fusion protein's mRNA. The second vector includes a second expression cassette containing an associated promoter that can be activated by the transcriptionally activated fusion protein, and a target gene downstream of the associated promoter. Advantages: This ensures that the target protein is expressed only in target cells and not in cancer cells, avoiding adverse effects on non-target cells or tissues, and reducing treatment risks and side effects.

The present invention provides a genetically modified non-human animal or the like that functionally lacks an endogenous ABCB1 gene and that functionally expresses the human ABCB1 gene, the genetically modified non-human animal or the like retaining a DNA construct for functionally expressing the human ABCB1 gene, wherein the DNA construct includes a coding sequence for the human ABCB1 gene, a CAR / PXR response element present in the 5' promoter region of the human ABCB1 gene, at least one intron of the human ABCB1 gene, and a sequence of the enhancer region present at the 3' end side of the human ABCB1 gene, and the DNA construct does not include at least a portion of the coding sequence for the human ABCB4 gene or includes only a portion of the human RUNDC3B gene.

This invention discloses a rose salt tolerance gene RrSPL13, its miRNA resistance target rRrSPL13, and its applications. This invention belongs to the field of plant genetic engineering technology. The nucleotide sequence of the RrSPL13 gene is shown in SEQ ID NO.1, and its protein amino acid sequence is shown in SEQ ID NO.2. This invention uses large primer mutagenesis technology to synonymously mutate the miRNA response element of the RrSPL13 gene, obtaining the miRNA resistance target rRrSPL13, whose nucleotide sequence is shown in SEQ ID NO.3. Under salt stress, RrSPL13 is post-transcriptionally regulated by miRNA, while rRrSPL13 is not regulated. After isolating the RrSPL13 gene from wild rose, it was transformed into Arabidopsis thaliana and 'Purple Branch' rose. The salt tolerance of the transgenic Arabidopsis thaliana and 'Purple Branch' rose was significantly enhanced, indicating that the RrSPL13 gene is a positive regulator of salt tolerance and has important application value in the field of breeding cultivated roses with salt tolerance and stress resistance.

The invention discloses an intelligent cell strain as well as a construction method and application thereof, belongs to the technical field of biology, and aims to solve the limitation of single-point static monitoring, strong equipment dependence or insufficient biological safety in the existing detection technology. The method comprises the following steps: constructing a response element PCMV-GRLBD-NES-TetR by using a truncated receptor GRLBD, inserting the response element PCMV-GRLBD-NES-TetR and a report element SB-PTCE-SEAP into a genome of a host fine HEK-293T cell, and selecting a monoclonal cell responding to glucocorticoid; wherein the report protein in the report element can also use other target proteins besides alkaline phosphatase (SEAP), including but not limited to tyrosinase (Tyrosinase) and red fluorescent protein (tdTomato). The cell strain can be used for developing high-throughput screening of targeted mental stress drug molecules, and material reserve is provided for development of anti-depression and anti-anxiety drugs.

The invention provides a high-sensitivity in-vitro pyrogen detection method, which is characterized in that on the basis of an in-vitro pyrogen detection method (reporter gene method), a transgenic cell which expresses a Toll-like receptor and transfects an NF-kB reaction element and a luciferase gene is used for detecting a pyrogen, the pyrogen is combined with the Toll-like receptor on the surface of the cell to activate an NF-kB signal channel, and the NF-kB reaction element and the luciferase gene are converted into the NF-kB signal channel. Therefore, the expression of luciferase is activated.

Oncolytic HSV vectors comprising NF-κB response elements or Oct-3 / 4-SOX2 response elements in the regulatory regions of viral genes that affect the efficiency of viral replication.

The present disclosure provides DNA molecules, such as transfer plasmids, useful for manufacturing packaged retroviral vectors encoding a therapeutic protein such as chimeric antigen receptors (CARs) and T cell receptors (TCRs). The encoded retroviral transcript in the DNA molecule includes a transgene, an elongation factor 1-alpha 1 (EF1α) promoter, without the EF1α intron, operably linked to the transgene and a Rev response element (RRE).

The invention relates to the technical field of gene engineering, in particular to application of a GhUGE2 gene in regulation and control of drought resistance of cotton. According to the invention, GhUGE gene family members are screened from upland cotton through whole genome identification, and the GhUGE2 gene is focused for functional analysis. Bioinformatics analysis reveals that the promoter region contains abundant stress response elements, and prompts that the promoter region participates in drought stress response. A GhUGE2 overexpression plant is constructed, it is found that the GhUGE2 overexpression plant shows a more drought-resistant phenotype after drought treatment, recovery is faster after rehydration, the water loss rate of in-vitro leaves is lower, active oxygen accumulation is slowed down, and meanwhile the antioxidant enzyme activity is remarkably improved. The GhUGE2 gene plays a core positive regulation role in the drought resistance of the cotton. The overexpression of the GhUGE2 can significantly improve the drought resistance phenotype of the cotton, and the results of physiological and biochemical indexes prove that the GhUGE2 improves the drought adaptability of the cotton by enhancing the active oxygen scavenging ability and maintaining the moisture balance.

Provided herein is a method for user controlled gene expression. In one embodiment, provided is a method for the activation of a T cell, comprising the steps of ectopically expressing farnesoid X receptor (FXR) in said T cell; activating said FXR; and transcribing a gene that contains a farnesoid response element (FRE) in a promoter region.

The invention belongs to the technical field of medical chemistry, and discloses a secondary amine PROTAC compound with the activity of degrading a nuclear receptor co-inhibitor 1 (NCoR1) in a targeted manner as well as a preparation method and application of the secondary amine PROTAC compound. The secondary amine compound is prepared through acylation and N-alkylation reaction, and the structure of the compound is shown as a formula I to a formula IV. A Liver X Receptor Response Element-Luciferase reporter gene system (LXRE-Luc luciferase reporter gene system) determination experiment shows that when the compound is 10 [mu] M, the compound has an obvious liver receptor (LXR) regulation effect, and the compound has an obvious liver receptor regulation effect when the compound is 10 [mu] M; western blot experiment research shows that the compound has a remarkable degradation effect on NCoR1, and the compound ZD-5 with the highest activity can generate a remarkable NCoR1 degradation effect when the concentration is 5 mu M. The compound is a protein degradation targeting chimera (PROTAC), has the advantages of being high in activity and easy and convenient to prepare, and has great value in the aspect of glycometabolism and ester metabolism regulation medicine development.